KMDA
Price
$7.17
Change
+$0.05 (+0.70%)
Updated
Jul 13 closing price
Capitalization
417.21M
36 days until earnings call
Intraday BUY SELL Signals
SIGA
Price
$3.61
Change
+$0.02 (+0.56%)
Updated
Jul 13 closing price
Capitalization
258.92M
16 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

KMDA vs SIGA

KMDA vs SIGA Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
KMDA vs. SIGA commentary
Jul 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KMDA is a Hold and SIGA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 14, 2026
Stock price -- (KMDA: $7.17 vs. SIGA: $3.61)
Brand notoriety: KMDA and SIGA are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: KMDA: 34% vs. SIGA: 68%
Market capitalization -- KMDA: $417.21M vs. SIGA: $258.92M
KMDA [@Pharmaceuticals: Generic] is valued at $417.21M. SIGA’s [@Pharmaceuticals: Generic] market capitalization is $258.92M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.97B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KMDA’s FA Score shows that 1 FA rating(s) are green whileSIGA’s FA Score has 2 green FA rating(s).

  • KMDA’s FA Score: 1 green, 4 red.
  • SIGA’s FA Score: 2 green, 3 red.
According to our system of comparison, SIGA is a better buy in the long-term than KMDA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KMDA’s TA Score shows that 5 TA indicator(s) are bullish while SIGA’s TA Score has 4 bullish TA indicator(s).

  • KMDA’s TA Score: 5 bullish, 3 bearish.
  • SIGA’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, KMDA is a better buy in the short-term than SIGA.

Price Growth

KMDA (@Pharmaceuticals: Generic) experienced а -4.27% price change this week, while SIGA (@Pharmaceuticals: Generic) price change was -3.73% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -3.88%. For the same industry, the average monthly price growth was +0.21%, and the average quarterly price growth was +13.40%.

Reported Earning Dates

KMDA is expected to report earnings on Aug 19, 2026.

SIGA is expected to report earnings on Jul 30, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-3.88% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KMDA($417M) has a higher market cap than SIGA($259M). KMDA has higher P/E ratio than SIGA: KMDA (20.49) vs SIGA (12.89). KMDA YTD gains are higher at: 4.636 vs. SIGA (-33.210). KMDA has higher annual earnings (EBITDA): 38.3M vs. SIGA (21.2M). SIGA has more cash in the bank: 146M vs. KMDA (23.1M). SIGA has less debt than KMDA: SIGA (538K) vs KMDA (11.5M). KMDA has higher revenues than SIGA: KMDA (182M) vs SIGA (93.8M).
KMDASIGAKMDA / SIGA
Capitalization417M259M161%
EBITDA38.3M21.2M181%
Gain YTD4.636-33.210-14%
P/E Ratio20.4912.89159%
Revenue182M93.8M194%
Total Cash23.1M146M16%
Total Debt11.5M538K2,138%
FUNDAMENTALS RATINGS
KMDA vs SIGA: Fundamental Ratings
KMDA
SIGA
OUTLOOK RATING
1..100
7466
VALUATION
overvalued / fair valued / undervalued
1..100
5
Undervalued
1
Undervalued
PROFIT vs RISK RATING
1..100
67100
SMR RATING
1..100
7968
PRICE GROWTH RATING
1..100
7182
P/E GROWTH RATING
1..100
7828
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SIGA's Valuation (1) in the Pharmaceuticals Other industry is in the same range as KMDA (5) in the Biotechnology industry. This means that SIGA’s stock grew similarly to KMDA’s over the last 12 months.

KMDA's Profit vs Risk Rating (67) in the Biotechnology industry is somewhat better than the same rating for SIGA (100) in the Pharmaceuticals Other industry. This means that KMDA’s stock grew somewhat faster than SIGA’s over the last 12 months.

SIGA's SMR Rating (68) in the Pharmaceuticals Other industry is in the same range as KMDA (79) in the Biotechnology industry. This means that SIGA’s stock grew similarly to KMDA’s over the last 12 months.

KMDA's Price Growth Rating (71) in the Biotechnology industry is in the same range as SIGA (82) in the Pharmaceuticals Other industry. This means that KMDA’s stock grew similarly to SIGA’s over the last 12 months.

SIGA's P/E Growth Rating (28) in the Pharmaceuticals Other industry is somewhat better than the same rating for KMDA (78) in the Biotechnology industry. This means that SIGA’s stock grew somewhat faster than KMDA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KMDASIGA
RSI
ODDS (%)
Bullish Trend 1 day ago
50%
Bullish Trend 1 day ago
88%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
71%
Bullish Trend 1 day ago
76%
Momentum
ODDS (%)
Bearish Trend 1 day ago
71%
Bearish Trend 1 day ago
75%
MACD
ODDS (%)
Bullish Trend 1 day ago
70%
Bearish Trend 1 day ago
77%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
62%
Bearish Trend 1 day ago
77%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
62%
Bearish Trend 1 day ago
79%
Advances
ODDS (%)
Bullish Trend 18 days ago
66%
Bullish Trend 1 day ago
80%
Declines
ODDS (%)
Bearish Trend 4 days ago
61%
Bearish Trend 5 days ago
73%
BollingerBands
ODDS (%)
Bullish Trend 5 days ago
56%
Bullish Trend 1 day ago
79%
Aroon
ODDS (%)
Bearish Trend 1 day ago
57%
Bearish Trend 1 day ago
70%
View a ticker or compare two or three
Interact to see
Advertisement
KMDA
Daily Signal:
Gain/Loss:
SIGA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CEVZX14.25N/A
N/A
Columbia Global Value Inst
MERIX17.27N/A
N/A
The Merger Fund I
FTHAX56.90N/A
N/A
FullerThaler Behavioral Sm-Cp Eq A
STRLX65.93N/A
N/A
Sterling Capital MdCp Relatv Val A
SVXYX93.85N/A
N/A
Smead International Value Y